Teva Loses 180-Day Exclusivity For Generic Actonel As FDA Stands Firm On Review Delays

Mylan’s product launches as FDA tells Teva that the agency’s delay in granting tentative ANDA approval does not prevent forfeiture of exclusivity.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet